Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03095872
Other study ID # 16-011
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date March 1, 2017
Est. completion date February 5, 2018

Study information

Verified date May 2018
Source RWTH Aachen University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In the field of dermatology the healing process and therefore the success of a laser treatment are strongly determined by an appropriate postoperative treatment of the laser-treated skin. The manufacturer of CO2 laser systems recommends the application of Vaseline postoperatively to protect the treated tissue from air exposition until encrustation of the laser-treated skin decreases (usually after 7-14 days). An alternative to Vaseline could be Bepanthen® "Wund- und Heilsalbe" (Bayer). It contains the active ingredient pro-vitamin Dexapanthenol, which is widely used in dermatology therapy. The product helps to stabilize the protective barrier of the skin, to reduce the skin irritation, to stimulate the skin regeneration and to promote the wound healing. In an in-vitro study Bepanthen® "Wund- und Heilsalbe" triggered wound closure significantly faster compared to Vaseline. In this study the effect of Bepanthen® "Wund- und Heilsalbe" on wound healing should be investigated and compared to Vaseline in vivo following fractional ablative CO2 laser treatment of photo-damaged skin.


Description:

The healing process and therefore the success of a laser treatment are strongly determined by an appropriate treatment with special skin care products of the laser-treated skin. Cooling measures prevent the swelling of the treated skin area, if applied directly after the procedure. A soothing and wound-healing-promoting care applied subsequently for seven days, can support and also speed up the healing process.

The Lumenis® Company is the manufacturer of CO2 laser systems and recommends the application of the Okklusiv ointment Vaseline® postoperatively, in order to prevent the treated tissue to the air exposition. These occlusive wound care should be maintained, until the encrustation of the laser-treated skin decreases, which usually happens 7-14 days postoperatively.

The Bepanthen® Wund- und Heilsalbe (Bayer) could be a possible alternative to Vaseline® as postoperative care. Bepanthen® Wund- und Heilsalbe contains pro-vitamin Dexpanthenol as an active ingredient and is widely used in dermatological therapy. The product helps to stabilize the protective barrier of the skin, to reduce the skin irritation, to stimulate the skin regeneration and to promote the wound healing. The investigators examined the effect of substances containing Dexpanthenol on wound healing process applied topically, in three-dimensional (3D) dermal skin equivalents in vitro. For this purpose, many lesions with standardized diameter and depth were generated using a laser. The subsequent topical application of substances containing dexpanthenol on the wound healing models (treated with laser) for three-days led to a significantly faster wound closure compared to Vaseline-covered models (Marquardt et al., 2015). The aim of this study is to compare the effect of white Vaseline with Bepanthen® "Wund- und Heilsalbe" (both applied postoperatively) on the wound healing following fractional ablative CO2 laser treatment of photo-damaged skin in vivo.


Recruitment information / eligibility

Status Completed
Enrollment 37
Est. completion date February 5, 2018
Est. primary completion date January 22, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age = 18 years

- photodamaged skin, which need to be treated with the fractional ablative CO2 laser

Exclusion Criteria:

- pregnant or lactating females

- chronic diseases such as diabetes and vascular disease with impaired wound healing

- Patients, who tend to form hypertrophic scars and keloids

- Patients, who take the isotretinoin-containing medication in the past year

- topical or systemic corticosteroid treatment

- immunocompromised patients

- Patients with the Koebner phenomenon

- People with the skin type 6

- Patients with melanoma

Study Design


Related Conditions & MeSH terms


Intervention

Device:
CO2-laser
Patients with photo-damaged skin are treated with the CO2 laser to remove damaged skin layers.
Drug:
Vaseline
After the laser treatment, the wound area will be divided into two parts with a sterile skin marker. One area will be treated with Vaseline, and be marked "V". Thus, it is ensured that the care product will be applied correctly to the defined area. Postoperatively, this area of the wound will be treated with Vaseline. In the next seven days the patient will repeat the treatment every day at home.
Bepanthen
After the laser treatment, the wound area will be divided into two parts with a sterile skin marker. One area will be treated with Bepanthen® Wund- und Heilsalbe, and be marked "B". Thus, it is ensured that the care product will be applied correctly to the defined area. Postoperatively, this area of the wound will be treated with Bepanthen® Wund- und Heilsalbe. In the next seven days the patient will repeat the treatment every day at home.

Locations

Country Name City State
Germany University Hospital RWTH Aachen Aachen NRW

Sponsors (1)

Lead Sponsor Collaborator
RWTH Aachen University

Country where clinical trial is conducted

Germany, 

References & Publications (4)

Bogdan Allemann I, Kaufman J. Laser principles. Curr Probl Dermatol. 2011;42:7-23. doi: 10.1159/000328236. Epub 2011 Aug 16. — View Citation

Marquardt Y, Amann PM, Heise R, Czaja K, Steiner T, Merk HF, Skazik-Voogt C, Baron JM. Characterization of a novel standardized human three-dimensional skin wound healing model using non-sequential fractional ultrapulsed CO2 laser treatments. Lasers Surg Med. 2015 Mar;47(3):257-65. doi: 10.1002/lsm.22341. Epub 2015 Mar 15. — View Citation

Reinholz M, Tietze JK, Kilian K, Schaller M, Schöfer H, Lehmann P, Zierhut M, Klövekorn W, Ruzicka T, Schauber J. Rosacea - S1 guideline. J Dtsch Dermatol Ges. 2013 Aug;11(8):768-80; 768-79. doi: 10.1111/ddg.12101. Epub 2013 May 6. English, German. — View Citation

Wigger-Alberti W, Kuhlmann M, Ekanayake S, Wilhelm D. Using a novel wound model to investigate the healing properties of products for superficial wounds. J Wound Care. 2009 Mar;18(3):123-28, 131. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change of the diameter of the individual lesions [initial value 1.3mm] between study visits. Large clinical digital photos as well as dermatoscopic images of the skin. Over 2 weeks (immediately after laser treatment and on day 1, 2, 5 and 14 after laser treatment)
Primary Change of the size of the individual lesions between study visits. Two-dimensional microscopic skin cut images in real time of the skin. Over 2 weeks (immediately after laser treatment and on day 1, 2, 5 and 14 after laser treatment)
Primary Visual changes of the wound healing between study visits. The wound healing rates will be visually assessed, based on the measure of re-epithelialization. Over 2 weeks (immediately after laser treatment and on day 1, 2, 5 and 14 after laser treatment)
Primary Change of the wound under cosmetic aspects between study visits. The cosmetic result is based on a visual analog scale (VAS) from 0 (bad) to 10 (excellent, with no visible difference of the wound to the surrounding tissue). Over 2 weeks (immediately after laser treatment and on day 1, 2, 5 and 14 after laser treatment)
Secondary Change of the transepidermal water loss (TEWL) between study visits. TEWL is the most important parameter for the assessment of skin barrier function. Over 2 weeks (immediately after laser treatment and on day 1, 2, 5 and 14 after laser treatment)
See also
  Status Clinical Trial Phase
Terminated NCT03573076 - Treatment of Photodamaged Skin of the décolleté Phase 4
Suspended NCT03963102 - Duration of Ameluz Application in Acral Actinic Keratoses Response Phase 4
Completed NCT01283464 - Comparison of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage and Wrinkles Phase 2
Active, not recruiting NCT06170346 - Effect of Topical Agents With Various Antioxidant Containts on Photodamage Skin Induced Phase 2
Completed NCT02736760 - Daylight-PDT With MAL for AK and Photodamaged Skin Phase 4
Active, not recruiting NCT05456334 - New Treatments for Actinic Keratoses of the Scalp N/A
Completed NCT05423873 - A Multi-Center, Open-label Study Evaluate the Efficacy and Tolerability of a Dual Skincare Regimen Treatment for Facial Hyperpigmentation and Photodamaged Skin in Patients Exposed to Extrinsic Factors of Aging N/A
Not yet recruiting NCT05908825 - Placebo-Controlled Study Assessing the Use of a Novel Exfoliative Serum With A Chemical Peel to Improve Photodamage in Adults N/A
Active, not recruiting NCT05963204 - A Study to Evaluate the Effects for Midface Improvement When Pairing a Biostimulator With a Skincare Regimen N/A
Recruiting NCT04523961 - Comparative Study of Two Topical Anesthetics Prior to Fractional Nonablative Laser Treatment of the Face Phase 2/Phase 3
Completed NCT01787461 - A Study to Assess the Effects of an Oral Dietary Supplement on Overall Facial Appearance Among Healthy Adult Women With Existing Skin Damage From Sun Exposure Phase 4
Recruiting NCT06351358 - Evaluation of the Effects of a Biostimulator and Dermal Fillers for Cheek Augmentation and Contour Deficiencies N/A
Completed NCT04065035 - A Clinical Study to Evaluate Efficacy and Tolerability of a Cosmetic Product for Arm Firming N/A
Active, not recruiting NCT04096742 - Altreno for Chest Rejuvenation Phase 4
Completed NCT02693054 - Safety and Efficacy Study for Various Skin Conditions N/A
Terminated NCT00375141 - Long-Pulsed Dye Laser and Intense Pulsed Light for Skin Rejuvenation. N/A